This document is a publication of a European patent application (EP3398612A1) related to stable formulations of antibodies targeting human programmed death receptor PD-1. The publication date is March 11, 2026, and the applicant is Merck Sharp & Dohme LLC. This is a patent disclosure, not a regulatory rule or guidance impacting compliance obligations.

As this is a patent publication, there are no immediate compliance actions required for regulated entities. Compliance officers should note this as a disclosure of intellectual property in the pharmaceutical sector, particularly concerning immunotherapies. Further analysis may be warranted if this patent leads to specific product approvals or market exclusivity claims impacting competitors.